Company news

Psyence Biomedical Ltd. news in 2024

Psyence Biomedical Ltd.'s news releases, calls and decks from 2024, newest first.

View company

Psyence Biomedical: Biomed Announces $2.0 Million Private Placement Form 6 K

December 22, 2024

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

December 22, 2024

Psyence Biomed Announces $2.0 Million Private Placement

December 22, 2024

Psyence Biomedical: Biomed Executes Binding Agreements with Optimi Health Corp Form 6 K

December 19, 2024

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

December 16, 2024

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

December 9, 2024

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

December 5, 2024

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

December 2, 2024

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

November 19, 2024

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

November 18, 2024

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

November 11, 2024

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

October 30, 2024

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

October 30, 2024

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

October 23, 2024

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

October 16, 2024

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

October 13, 2024

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

October 3, 2024

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

September 19, 2024

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

September 18, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

September 15, 2024

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

September 15, 2024

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

September 12, 2024

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

September 8, 2024

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

September 5, 2024

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

September 3, 2024

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

August 29, 2024

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

July 30, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

July 25, 2024

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

July 23, 2024

Decks in 2024